• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

    8/13/25 4:14:05 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBH alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Prestige Consumer Healthcare I

    (Name of Issuer)


    Common Stock SH

    (Title of Class of Securities)


    74112D101

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    74112D101


    1Names of Reporting Persons

    Ariel Investments, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,950,287.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,202,327.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,202,327.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Prestige Consumer Healthcare I
    (b)Address of issuer's principal executive offices:

    660 WHITE PLAINS RD., TARRYTOWN, NY, 10591
    Item 2. 
    (a)Name of person filing:

    Ariel Investments, LLC
    (b)Address or principal business office or, if none, residence:

    200 E. Randolph Street, Suite 2900, Chicago, 60601, United States
    (c)Citizenship:

    DELAWARE LIMITED LIABILITY COMPANY
    (d)Title of class of securities:

    Common Stock SH
    (e)CUSIP No.:

    74112D101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,202,327
    (b)Percent of class:

    4.5  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    1,950,287

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    2,202,327

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Ariel Investments, LLC's adviser clients have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, all securities reported upon this Schedule. None of Ariel Investments, LLC's clients have an economic interest in more than 5% of the subject securities reported upon this Schedule.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Ariel Investments, LLC
     
    Signature:James Prescott
    Name/Title:Vice President, Compliance
    Date:08/13/2025
    Get the next $PBH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBH

    DatePrice TargetRatingAnalyst
    9/24/2025$80.00Neutral → Buy
    Sidoti
    12/9/2024$90.00Buy → Neutral
    Sidoti
    6/21/2024$65.00 → $93.00Neutral → Buy
    DA Davidson
    11/17/2022$71.00Buy
    Canaccord Genuity
    5/10/2022$65.00 → $70.00Hold → Buy
    Jefferies
    5/9/2022$63.00Perform → Outperform
    Oppenheimer
    3/11/2022$156.00 → $142.00Outperform
    BMO Capital
    11/15/2021$61.00 → $63.00Neutral
    DA Davidson
    More analyst ratings

    $PBH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results

    TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thursday, November 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to joi

    10/6/25 5:00:00 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference

    TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced it will present at the Barclays Global Consumer Staples Conference on Thursday, September 4, 2025 at 12:45 p.m. ET. All interested parties may access a live webcast of this event at www.prestigeconsumerhealthcare.com under the "Investors" section and the "Events and Presentations" tab, or by using the following link: https://ir.prestigebrands.com/events-presentations/events For those unable to participate during the live webcast, a replay option will be available on the Company's website following the event. About Prestige Consumer Healthcare Inc. Prestige Consumer H

    9/4/25 7:00:03 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results

    Revenue of $249.5 million in Q1; decline driven by limited eye care supplyDiluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90Announces agreement to acquire current eye care supplier Pillar5 PharmaRevising fiscal 2026 revenue outlook to $1,100 to $1,115 million and Diluted EPS outlook to $4.50 to $4.58 TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2026 ended June 30, 2025. "We experienced momentum in multiple areas of our business in the first quarter, including strong international segment growth, year-over-year improvement in gross m

    8/7/25 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Prestige Consumer upgraded by Sidoti with a new price target

    Sidoti upgraded Prestige Consumer from Neutral to Buy and set a new price target of $80.00

    9/24/25 7:53:30 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer downgraded by Sidoti with a new price target

    Sidoti downgraded Prestige Consumer from Buy to Neutral and set a new price target of $90.00

    12/9/24 9:05:37 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer upgraded by DA Davidson with a new price target

    DA Davidson upgraded Prestige Consumer from Neutral to Buy and set a new price target of $93.00 from $65.00 previously

    6/21/24 7:05:28 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    SEC Filings

    View All

    $PBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Prestige Consumer Healthcare Inc.

    SCHEDULE 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    8/13/25 4:14:05 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Prestige Consumer Healthcare Inc.

    10-Q - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

    8/7/25 6:15:06 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Prestige Consumer Healthcare Inc. (0001295947) (Filer)

    8/7/25 6:07:11 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kelly John F. was granted 2,094 shares, increasing direct ownership by 76% to 4,851 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    8/6/25 4:05:36 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zier Dawn M. was granted 2,094 shares, increasing direct ownership by 15% to 16,533 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    8/6/25 4:04:46 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hopkins Sheila was granted 2,094 shares, increasing direct ownership by 7% to 30,123 units (SEC Form 4)

    4 - Prestige Consumer Healthcare Inc. (0001295947) (Issuer)

    8/6/25 4:03:43 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Leadership Updates

    Live Leadership Updates

    View All

    Better For You Wellness Announces Results from Its February 5, 2022, Board of Directors Meeting

    Better For You Wellness Establishes Strategic Advisory Committee with Industry Leaders and MoreColumbus, Ohio--(Newsfile Corp. - February 10, 2022) - Better For You Wellness, Inc. (OTCQB:BFYW) ("Better For You Wellness" or the "Company"), an Ohio-based company focused on the rapidly-growing $1.5T wellness industry, is pleased to announce the results of the Meeting of the Board of Directors that took place on February 5, 2022, via video conference (the "Board Meeting"). The seven members of the Company's Board of Directors (the "Board") include Ian James, Stephen Letourneau, Montel Williams, Christina Jefferson, Joseph Watson, David Deming, and Dr. Nicola Finley, MD.Establishment of Strategic

    2/10/22 3:58:00 PM ET
    $LEAF
    $PBH
    $SPTN
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

    SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/14/24 10:11:25 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Prestige Consumer Healthcare Inc.

    SC 13G - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/14/24 7:09:49 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Prestige Consumer Healthcare Inc. (Amendment)

    SC 13G/A - Prestige Consumer Healthcare Inc. (0001295947) (Subject)

    2/13/24 5:12:15 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PBH
    Financials

    Live finance-specific insights

    View All

    Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results

    TARRYTOWN, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 second quarter and first half earnings release on Thursday, November 6, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to joi

    10/6/25 5:00:00 PM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results

    Revenue of $249.5 million in Q1; decline driven by limited eye care supplyDiluted EPS of $0.95 in Q1, up approximately 6% versus prior year Adjusted Diluted EPS of $0.90Announces agreement to acquire current eye care supplier Pillar5 PharmaRevising fiscal 2026 revenue outlook to $1,100 to $1,115 million and Diluted EPS outlook to $4.50 to $4.58 TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2026 ended June 30, 2025. "We experienced momentum in multiple areas of our business in the first quarter, including strong international segment growth, year-over-year improvement in gross m

    8/7/25 6:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prestige Consumer Healthcare to Release Fiscal 2026 First Quarter Earnings Results

    TARRYTOWN, N.Y., July 15, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 first quarter earnings release on Thursday, August 7, 2025 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes

    7/15/25 8:00:00 AM ET
    $PBH
    Biotechnology: Pharmaceutical Preparations
    Health Care